iBio Management

Management criteria checks 3/4

iBio's CEO is Martin Brenner, appointed in Jan 2021, has a tenure of 3.33 years. total yearly compensation is $1.07M, comprised of 42.8% salary and 57.2% bonuses, including company stock and options. directly owns 0.075% of the company’s shares, worth $11.04K. The average tenure of the management team and the board of directors is 2.8 years and 6.6 years respectively.

Key information

Martin Brenner

Chief executive officer

US$1.1m

Total compensation

CEO salary percentage	42.8%
CEO tenure	3.3yrs
CEO ownership	0.07%
Management average tenure	2.8yrs
Board average tenure	6.6yrs

Recent management updates

Recent updates

iBio's (NYSEMKT:IBIO) Wonderful 324% Share Price Increase Shows How Capitalism Can Build Wealth

Jan 07

CEO Compensation Analysis

How has Martin Brenner's remuneration changed compared to iBio's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-US$21m
Sep 30 2023	n/a	n/a	-US$27m
Jun 30 2023	US$1m	US$458k	-US$29m
Mar 31 2023	n/a	n/a	-US$56m
Dec 31 2022	n/a	n/a	-US$35m
Sep 30 2022	n/a	n/a	-US$32m
Jun 30 2022	US$1m	US$405k	-US$30m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	n/a	n/a	-US$20m
Sep 30 2021	n/a	n/a	-US$21m
Jun 30 2021	US$1m	US$178k	-US$23m

Compensation vs Market: Martin's total compensation ($USD1.07M) is above average for companies of similar size in the US market ($USD667.63K).

Compensation vs Earnings: Martin's compensation has been consistent with company performance over the past year.

CEO

Martin Brenner (52 yo)

3.3yrs

Tenure

US$1,069,174

Compensation

Dr. Martin B. Brenner DVM., Ph D., is Chief Executive Officer of iBio, Inc. from June 27, 2023. Dr. Brenner was Interim CEO of iBio, Inc. from January 20, 2023 to June 27, 2023 and has been its Chief Scie...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Martin Brenner	CEO & Chief Scientific Officer	3.3yrs	US$1.07m	0.075% $ 11.0k
Felipe Duran	Chief Financial Officer	1.3yrs	US$1.23m	0.014% $ 2.1k
Stephen Kilmer	Investor Relations Officer	no data	no data	no data
Marc Banjak	General Counsel	2.2yrs	no data	no data
Robert Kay	Interim Secretary & Interim Treasurer	3.7yrs	US$92.69k	no data

2.8yrs

Average Tenure

52yo

Average Age

Experienced Management: IBIO's management team is considered experienced (2.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Robert Erwin	Member of Scientific Advisory Board	3.4yrs	US$291.75k	no data
William Clark	Independent Chairman	2.8yrs	US$73.01k	0.0042% $ 618.5
Gary Sender	Lead Independent Director	3.6yrs	US$71.41k	0.0049% $ 714.2
Vidadi Yusibov	Member of Scientific Advisory Board	19.7yrs	no data	no data
James Hill	Independent Director	15.8yrs	US$55.00k	0.0046% $ 675.9
Timothy Blackwell	Member of Clinical Advisory Board	9.8yrs	no data	no data
Richard Silver	Member of Clinical Advisory Board	9.8yrs	no data	no data
J. Huggins	Member of Clinical Advisory Board	9.8yrs	no data	no data
Thomas Medsger	Member of Clinical Advisory Board	9.7yrs	no data	no data
Evert Schimmelpennink	Independent Director	2.9yrs	US$57.50k	0.0043% $ 639.1
Linda Armstrong	Independent Director	3.6yrs	US$63.50k	0.0049% $ 714.2
Alexandra Kropotova	Independent Director	3.6yrs	US$52.50k	0.0049% $ 714.2

6.6yrs

Average Tenure

60.5yo

Average Age

Experienced Board: IBIO's board of directors are considered experienced (6.6 years average tenure).

iBio Management

Management criteria checks 3/4

Key information

Recent management updates

iBio, Inc., Annual General Meeting, Nov 27, 2023

iBio, Inc. Appoints Dr. Martin Brenner as CEO

iBio, Inc. Appoints Felipe Duran as Interim Chief Financial Officer, Effective as of February 13, 2023

iBio, Inc. Announces Resignation of Robert Lutz, the Chief Financial and Business Officer as an Executive Officer, Effective February 10, 2023

High number of new and inexperienced directors

iBio, Inc. Announces Executive Changes

Recent updates

iBio, Inc. announced that it has received $15.066157 million in funding from ADAR1 Capital Management, LLC, Lynx1 Capital Management LP, Ikarian Capital, LLC

iBio, Inc. announced that it expects to receive $15.068742 million in funding from ADAR1 Capital Management, LLC, Lynx1 Capital Management LP, Ikarian Capital, LLC and other investors

New major risk - Financial position

iBio, Inc. has completed a Follow-on Equity Offering in the amount of $4.780385 million.

New major risk - Financial position

iBio, Inc. Announces Expansion of its AI-Powered Technology Stack with Launch of ShieldTx

iBio, Inc., Annual General Meeting, Nov 27, 2023

New minor risk - Insider selling

New major risk - Market cap size

iBio, Inc. Appoints Dr. Martin Brenner as CEO

iBio, Inc. Announces the Expansion of Its AI-Powered Technology Stack with the Launch of EngageTx

Third quarter 2023 earnings released: US$0.48 loss per share (vs US$1.42 loss in 3Q 2022)

iBio Announces MUC16 as its Latest Immune-Oncology Target Program

First half 2023 earnings released: US$1.93 loss per share (vs US$1.97 loss in 1H 2022)

iBio, Inc. Appoints Felipe Duran as Interim Chief Financial Officer, Effective as of February 13, 2023

iBio, Inc. Announces Resignation of Robert Lutz, the Chief Financial and Business Officer as an Executive Officer, Effective February 10, 2023

High number of new and inexperienced directors

iBio, Inc. has completed a Follow-on Equity Offering in the amount of $3.5 million.

iBio, Inc. to Showcase the RubrYc Discovery Engine During Poster Presentations At Antibody Engineering & Therapeutics Conference 2022

iBio, Inc. Announces Executive Changes

iBio, Inc. Announces the Resignation of Thomas F. Isett as a Member of the Board

iBio, Inc. Appoints William D. (Chip) Clark as Chairman

iBio, Inc., Annual General Meeting, Dec 08, 2022

iBio, Inc. Files a Provisional Patent with the United States Patent and Trademark Office Title 'Epidermal Growth Factor Receptor Variant III Antibodies'

iBio, Inc. announced delayed annual 10-K filing

iBio, Inc. to Report Q4, 2022 Results on Sep 27, 2022

iBio Provides Update on Development of Next-Gen COVID-19 Vaccine Candidate

Consensus forecasts updated

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

iBio, Inc. to Report Q3, 2022 Results on May 12, 2022

Price target decreased to US$1.75

Consensus revenue estimates fall by 52%

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

iBio, Inc. to Report Q2, 2022 Results on Feb 14, 2022

iBio, Inc. Shares an Update on Its Lead COVID-19 Vaccine Program, IBIO-202

iBio, Inc Announces Update for its Lead COVID-19 Vaccine Program, IBIO-202, in Light of the Emergence of the Omicron (B.1.1.529) Variant of SARS-CoV-2

Price target decreased to US$2.25

First quarter 2022 earnings released: US$0.041 loss per share (vs US$0.047 loss in 1Q 2021)

iBio, Inc. Provides Revenue Guidance for the First Half, Second Half and Full Year of Fiscal 2022

Full year 2021 earnings released: US$0.12 loss per share (vs US$0.61 loss in FY 2020)

Independent Director Seymour Flug has left the company

High number of new directors

iBio Reports Successful Preclinical Immunization Studies with Next-Gen Nucleocapsid COVID-19 Vaccine Candidate

iBio, Inc.(NYSEAM:IBIO) dropped from Russell Microcap Growth Index

Third quarter 2021 earnings released: US$0.036 loss per share (vs US$0.059 loss in 3Q 2020)

iBio, Inc. Reports Successful Covid-19 Vaccine Toxicology Study Results and Announces Next-Gen Covid-19 Vaccine Program

iBio, Inc. and Fraunhofer USA, Inc. Concludes Litigation

Revenue beats expectations

Second quarter 2021 earnings released: US$0.043 loss per share (vs US$0.69 loss in 2Q 2020)

iBio, Inc. Appoints Robert M. Lutz as Chief Financial & Business Officer, Effective March 4, 2021

iBio, Inc. to Report Q2, 2021 Results on Feb 16, 2021

New 90-day high: US$2.17

iBio's (NYSEMKT:IBIO) Wonderful 324% Share Price Increase Shows How Capitalism Can Build Wealth

New 90-day low: US$1.08

iBio Appoints Dr. Martin B. Brenner as Chief Scientific Officer

Price target lowered to US$2.00

iBio, Inc. Announces Resignation of Robert L. Erwin as President

iBio, Inc. has completed a Follow-on Equity Offering in the amount of $32.493644 million.

iBio to Produce ATB Therapeutics’ Bioengineered Antibody-Toxin Fusion Proteins

iBio, Inc. to Report Q1, 2021 Results on Nov 16, 2020

iBio, Inc. Appoints Randy J. Maddux as Chief Operating Officer, Effective December 1, 2020

iBio, Inc. Announces Appointment of Members to Committees

iBio, Inc. Appoints Gary Sender to Its Board of Directors

iBio, Inc. Announces the Appointment of Linda Armstrong to Board of Directors

iBio Regains Compliance with NYSE American Continued Listing Standards

iBio Enters into Agreement with Safi Biosolutions to Develop Growth Factors and Cytokines Using the FastPharming® System

iBio, Inc. announced delayed annual 10-K filing

CEO Compensation Analysis

CEO